Antibody–Drug Conjugates in the Treatment of Urothelial Cancer
Antibody–Drug Conjugates in the Treatment of Urothelial Cancer
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Antibody–drug conjugates (ADCs) have transformed the treatment landscape in oncology and become an essential therapeutic modality. In urothelial carcinoma (UC), the two ADCs that have been especially successful in clinical practice are enfortumab vedotin and sacituzumab govitecan. These drugs are currently approved as monotherapy for later lines of...
Alternative Titles
Full title
Antibody–Drug Conjugates in the Treatment of Urothelial Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2821341633
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2821341633
Other Identifiers
ISSN
1173-8804,1179-190X
E-ISSN
1179-190X
DOI
10.1007/s40259-023-00606-5
